{
  "docId": "019de071-f36b-702d-acba-b009d415a6aa",
  "docSlug": "7f10ea97b4031d406788e9f98a2cb8e4",
  "documentTitle": "Alkermes | Investor Conference Presentation Deck | 36 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 28,
  "pageCount": 36,
  "prevPage": 27,
  "nextPage": 29,
  "slideType": "propose_solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-f36b-702d-acba-b009d415a6aa/28",
  "deckHref": "/decks/019de071-f36b-702d-acba-b009d415a6aa",
  "deckJsonHref": "/decks/019de071-f36b-702d-acba-b009d415a6aa.json",
  "deckAnchorHref": "/decks/019de071-f36b-702d-acba-b009d415a6aa#slide-28",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.05,
        "x": 0.71,
        "y": 0.83
      },
      "kind": "image",
      "text": "Syringe icon",
      "attrs": null,
      "subkind": "iconography",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "312474fa-3f7f-4c92-94c9-d94a783fae6d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.05,
        "x": 0.71,
        "y": 0.48
      },
      "kind": "image",
      "text": "IV bag icon",
      "attrs": null,
      "subkind": "iconography",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "82328e09-5d9b-4684-b0f1-1a9af4ebeea5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.05,
        "x": 0.23,
        "y": 0.72
      },
      "kind": "image",
      "text": "IV bag icon",
      "attrs": null,
      "subkind": "iconography",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b10a3bd8-dc43-4703-9b26-e1f9e30d97d6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.5,
        "y": 0.2
      },
      "kind": "list",
      "text": "Less frequent IV dosing: Extensive PK/PD modeling; Advancement into clinic expected Q1'22.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0216b6ce-26aa-4e49-a850-4cf52677ebc4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.4,
        "x": 0.05,
        "y": 0.3
      },
      "kind": "list",
      "text": "Daily IV x5: Achieved proof-of-concept; Demonstrated anti-tumor activity; Established safety profile; Advanced into registrational studies.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "afd921ff-d5e8-40bb-bb3d-fe6de9c76787",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.5,
        "y": 0.55
      },
      "kind": "list",
      "text": "Subcutaneous once-weekly dosing: Initial PK/PD, safety and tolerability profile observed; Identified recommended phase 2 dose; Evaluating anti-tumor activity.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f14389d9-93bc-4a7d-a976-3da042a565b0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Nemvaleukin: Evaluating Multiple Potential Dosing Options to Provide Flexibility and Support Broader Clinical Utility",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "111feee6-4e10-4b22-b1a7-07286294f68c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "fde81ab7-bec5-462b-a135-05b5277daa61",
      "evidence": "The slide contains a list of bullet points describing different dosing options for Nemvaleukin.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 34,
      "from": 23,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "4e1affb3-fc2c-436d-a5c0-492bd8d09819",
      "evidence": "The deck presents an overview of the innovation pipeline and its potential benefits",
      "position": 0,
      "objective": "Highlighting the importance of Alkermes' innovation pipeline",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}